EGFR and chronic obstructive pulmonary disease: In terms of PFS, significant differences were observed in patients ≥1 months after EGFR‐TKI treatment (p = 0.042, hazard ratio [HR] = 0.55, 95% confidence interval [CI] = 0.31–0.98), with a low BMI (body mass index) level (p = 0.042, HR = 0.73, 95% CI = 0.54–0.99), and without chronic obstructive pulmonary disease (COPD) (p = 0.005, HR = 0.36, 95% CI = 0.17–0.75).